Found: 5
Select item for more details and to access through your institution.
Preclinical Development of <sup>18</sup>F-OF-NB1 for Imaging GluN2BContaining N-Methyl-D-Aspartate Receptors and its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.246785
- By:
- Publication type:
- Article
Preclinical Development of <sup>18</sup>F-OF-NB1 for Imaging GluN2BContaining N-Methyl-D-Aspartate Receptors and its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.246785
- By:
- Publication type:
- Article
Preclinical Development of 18F-OF-NB1 for Imaging GluN2BContaining N-Methyl-D-Aspartate Receptors and its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.246785
- By:
- Publication type:
- Article
Preclinical Development of <sup>18</sup>F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-D-Aspartate Receptors and its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.246785
- By:
- Publication type:
- Article
Liquid Chromatography ICP-MS to Assess the Stability of 175 Lu- and nat Ga-Based Tumor-Targeting Agents towards the Development of 177 Lu- and 68 Ga-Labeled Radiopharmaceuticals.
- Published in:
- Pharmaceutics, 2024, v. 16, n. 3, p. 299, doi. 10.3390/pharmaceutics16030299
- By:
- Publication type:
- Article